Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

View More View Less
  • 1 Roswell Park Comprehensive Cancer Center;
  • | 2 Children’s of Alabama/O’Neal Comprehensive Cancer Center at UAB;
  • | 3 City of Hope National Medical Center;
  • | 4 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • | 5 Indiana University Melvin and Bren Simon Comprehensive Cancer Center;
  • | 6 University of Michigan Rogel Cancer Center;
  • | 7 UC Davis Comprehensive Cancer Center;
  • | 8 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center;
  • | 9 UCSD Rady Children’s Hospital/UC San Diego Moores Cancer Center;
  • | 10 Fred & Pamela Buffett Cancer Center;
  • | 11 Mayo Clinic Cancer Center;
  • | 12 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • | 13 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;
  • | 14 University of Wisconsin Carbone Cancer Center;
  • | 15 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • | 16 Children’s Hospital of Colorado/University of Colorado Cancer Center;
  • | 17 Stanford Cancer Institute;
  • | 18 Duke Cancer Center;
  • | 19 The University of Texas MD Anderson Cancer Center;
  • | 20 UT Southwestern Simmons Comprehensive Cancer Center;
  • | 21 Abramson Cancer Center at the University of Pennsylvania;
  • | 22 Memorial Sloan Kettering Cancer Center;
  • | 23 UCLA Jonsson Comprehensive Cancer Center;
  • | 24 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • | 25 Vanderbilt-Ingram Cancer Center; and
  • | 26 National Comprehensive Cancer Network.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Aggressive Mature B-Cell Lymphomas include recommendations for the diagnosis and management of pediatric patients with primary mediastinal large B-cell lymphoma (PMBL) and sporadic variants of Burkitt lymphoma and diffuse large B-cell lymphoma. PMBL is now considered as a distinct entity arising from mature thymic B-cells accounting for 2% of mature B-cell lymphomas in children and adolescents. This discussion section includes the recommendations outlined in the NCCN Guidelines for the diagnosis and management of pediatric patients with PMBL.

Individual Disclosures for the Pediatric Aggressive Mature B-Cell Lymphomas Panel
Individual Disclosures for the Pediatric Aggressive Mature B-Cell Lymphomas Panel

  • 1.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:733.

  • 2.

    National Cancer Institute. Cancer stat facts: cancer among adolescents and young adults (AYAs) (ages 15–39). Accessed September 2, 2022. Available at: https://seer.cancer.gov/statfacts/html/aya.html

    • Search Google Scholar
    • Export Citation
  • 3.

    Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005;131:3949.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Hochberg J, Waxman IM, Kelly KM, et al. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol 2009;144:2440.

  • 5.

    Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. Hematology Am Soc Hematol Educ Program 2016;2016:589597.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Pfister SM, Reyes-Múgica M, Chan JKC, et al. A summary of the inaugural WHO Classification of Pediatric Tumors: transitioning from the optical into the molecular era. Cancer Discov 2022;12:331355.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon, France: IARC; 2017.

    • Search Google Scholar
    • Export Citation
  • 8.

    Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d’Etude des Lymphomes de l’Adulte”) study. Am J Surg Pathol 1996;20:877888.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Oschlies I, Burkhardt B, Salaverria I, et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 2011;96:262268.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 2004;22:30463052.

  • 11.

    Satturwar S, Rekhtman N, Lin O, et al. An update on touch preparations of small biopsies. J Am Soc Cytopathol 2020;9:322331.

  • 12.

    Pileri SA, Zinzani PL, Gaidano G, et al. Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma 2003;44(Suppl 3):S2126.

  • 13.

    Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851862.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:38713879.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Wessendorf S, Barth TF, Viardot A, et al. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia 2007;21:24632469.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Attias D, Hodgson D, Weitzman S. Primary mediastinal B-cell lymphoma in the pediatric patient: can a rational approach to therapy be based on adult studies? Pediatr Blood Cancer 2009;52:566570.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Roberts RA, Wright G, Rosenwald AR, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 2006;108:311318.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Mottok A, Woolcock B, Chan FC, et al. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep 2015;13:14181431.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Joos S, Otaño-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 1996;87:15711578.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Bentz M, Barth TF, Brüderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 2001;30:393401.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Weniger MA, Pulford K, Gesk S, et al. Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma. Leukemia 2006;20:18801882.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Weniger MA, Gesk S, Ehrlich S, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer 2007;46:406415.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010;116:32683277.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014;123:20622065.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Riad R, Omar W, Kotb M, et al. Role of PET/CT in malignant pediatric lymphoma. Eur J Nucl Med Mol Imaging 2010;37:319329.

  • 26.

    Seidemann K, Tiemann M, Lauterbach I, et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group. J Clin Oncol 2003;21:17821789.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Gerrard M, Waxman IM, Sposto R, et al. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood 2013;121:278285.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Dourthe ME, Phulpin A, Auperin A, et al. Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study. Haematologica. Published online September 1, 2022. doi: 10.3324/haematol.2021.280257

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH- rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:14081416.

  • 30.

    Hayden AR, Tonseth P, Lee DG, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood 2020;136:28032811.

  • 31.

    Giulino-Roth L, O’Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose- adjusted EPOCH-R. Br J Haematol 2017;179:739747.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Knörr F, Zimmermann M, Attarbaschi A, et al. Dose-adjusted EPOCH- rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma. Haematologica 2021;106:32323235.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Burke GAA, Minard-Colin V, Aupérin A, et al. Dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab therapy in children and adolescents with primary mediastinal B-Cell lymphoma: a multicenter phase II trial. J Clin Oncol 2021;39:37163724.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Giulino-Roth L. How I treat primary mediastinal B-cell lymphoma. Blood 2018;132:782790.

  • 35.

    Eissa HM, Allen CE, Kamdar K, et al. Pediatric Burkitt’s lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Pediatr Hematol Oncol 2014;31:253257.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Avivi I, Boumendil A, Finel H, et al. Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2018;53:10011009.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Vardhana S, Hamlin PA, Yang J, et al. Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant 2018;24:21332138.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38.

    Moleti ML, Testi AM, Foà R. Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 2020;189:826843.

  • 39.

    Zinzani PL, Pellegrini C, Chiappella A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood 2017;129:23282330.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 2017;130:267270.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Zinzani PL, Santoro A, Gritti G, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study. J Clin Oncol 2019;37:30813089.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-Cell lymphoma. J Clin Oncol 2019;37:32913299.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43.

    Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 2020;21:541550.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19- directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol 2021;96:12951312.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439448.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 46.

    Fakhri B, Ai W. Current and emerging treatment options in primary mediastinal B-cell lymphoma. Ther Adv Hematol 2021;12:20406207211048959.

  • 47.

    Kohorst MA, Nunez CA, Tewari P, et al. Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy. Br J Haematol 2020;190:e114117.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 539 539 539
PDF Downloads 404 404 404
EPUB Downloads 0 0 0